Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.21), $0.09 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $22.8 million versus the consensus estimate of $23.02 million.

GUIDANCE:

Y-mAbs Therapeutics sees FY2024 revenue of $87-95 million, versus the consensus of $95.18 million.

Anticipated Operating Expenses expected to remain between $115 million and $120 million;
Anticipated Total Annual Cash Burn expected to remain between $15 million and $20 million; and
Cash and Cash Equivalents anticipated to continue to support operations as currently planned into 2027.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.